Cover Image
市場調查報告書

偏頭痛:開發平台分析

Migraine - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232767
出版日期 內容資訊 英文 221 Pages
訂單完成後即時交付
價格
Back to Top
偏頭痛:開發平台分析 Migraine - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 221 Pages
簡介

偏頭痛的特徵是不斷重複來襲的頭痛,通常都只有半邊頭陣陣發疼。這樣的頭痛多半會伴隨著噁心,嘔吐,畏光或畏聲等對光聲過度反應。症狀有出聲障礙、臉或手臂、臂膀感到刺痛、日常身體動作惡化等。

本報告提供偏頭痛的治療藥開發平台現狀及各開發階段比較分析,提供您最新更新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

偏頭痛概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Achelios Therapeutics, Inc.
  • Acorda Therapeutics, Inc.
  • Afferent Pharmaceuticals, Inc.
  • Alder Biopharmaceuticals Inc.
  • Allergan Plc
  • Amgen Inc.
  • Aralez Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Charleston Laboratories, Inc.
  • CoLucid Pharmaceuticals, Inc.
  • Corium International, Inc.
  • D-Pharm Ltd.
  • Eli Lilly and Company
  • iCeutica, Inc.
  • Impel NeuroPharma, Inc.
  • Klaria Pharma Holding AB
  • Mallinckrodt Plc
  • Medestea Research & Production S.p.A.
  • Merck & Co., Inc.
  • Mithra Pharmaceuticals S.A.
  • Monosol Rx, LLC
  • NAL Pharmaceuticals Ltd.
  • Noxxon Pharma AG
  • 大塚集團
  • Pivot Pharmaceuticals Inc
  • Promius Pharma, LLC
  • RedHill Biopharma Ltd.
  • Revance Therapeutics, Inc.
  • 新日本科學
  • Suda Ltd
  • Teva Pharmaceutical Industries Ltd.
  • TheraJect, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Trevena, Inc.
  • Trigemina, Inc.
  • Vertex Pharmaceuticals Incorporated
  • Zosano Pharma Corporation

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8702IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Pipeline Review, H2 2016, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 12, 14, 14, 20, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 3 molecules, respectively.Migraine.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 8
  • Introduction 9
  • Global Markets Direct Report Coverage 9
  • Migraine Overview 10
  • Therapeutics Development 11
  • Pipeline Products for Migraine - Overview 11
  • Pipeline Products for Migraine - Comparative Analysis 12
  • Migraine - Therapeutics under Development by Companies 13
  • Migraine - Therapeutics under Investigation by Universities/Institutes 17
  • Migraine - Pipeline Products Glance 18
  • Late Stage Products 18
  • Clinical Stage Products 19
  • Early Stage Products 20
  • Unknown Stage Products 21
  • Migraine - Products under Development by Companies 22
  • Migraine - Products under Investigation by Universities/Institutes 26
  • Migraine - Companies Involved in Therapeutics Development 27
  • Achelios Therapeutics Inc 27
  • Acorda Therapeutics Inc 28
  • Afferent Pharmaceuticals Inc 29
  • Alder Biopharmaceuticals Inc 30
  • Allergan Plc 31
  • Amgen Inc 32
  • Aralez Pharmaceuticals Inc 33
  • Astellas Pharma Inc 34
  • Biofrontera AG 35
  • BioHealthonomics Inc 36
  • Bristol-Myers Squibb Company 37
  • Charleston Laboratories Inc 38
  • CoLucid Pharmaceuticals Inc 39
  • Corium International Inc 40
  • Eli Lilly and Company 41
  • Impel NeuroPharma Inc 42
  • InStar Technologies AS 43
  • Klaria Pharma Holding AB 44
  • Medestea Research & Production SpA 45
  • Merck & Co Inc 46
  • Mithra Pharmaceuticals SA 47
  • Monosol Rx LLC 48
  • NAL Pharmaceuticals Ltd 49
  • Noxxon Pharma AG 50
  • Otsuka Holdings Co Ltd 51
  • Promius Pharma LLC 52
  • RedHill Biopharma Ltd 53
  • Revance Therapeutics Inc 54
  • Shin Nippon Biomedical Laboratories Ltd 55
  • Strategic Science & Technologies LLC 56
  • Suda Ltd 57
  • Teva Pharmaceutical Industries Ltd 58
  • TheraJect Inc 59
  • Tonix Pharmaceuticals Holding Corp 60
  • Trevena Inc 61
  • Trigemina Inc 62
  • TrioxBio Inc 63
  • Vertex Pharmaceuticals Inc 64
  • Xenon Pharmaceuticals Inc 65
  • Zosano Pharma Corp 66
  • Migraine - Therapeutics Assessment 67
  • Assessment by Monotherapy Products 67
  • Assessment by Combination Products 68
  • Assessment by Target 69
  • Assessment by Mechanism of Action 74
  • Assessment by Route of Administration 79
  • Assessment by Molecule Type 81
  • Drug Profiles 83
  • (dextromethorphan + quinidine sulfate) - Drug Profile 83
  • (naproxen sodium + sumatriptan succinate) - Drug Profile 88
  • (promethazine [INN] + sumatriptan succinate) - Drug Profile 90
  • AA-71 - Drug Profile 91
  • AF-130 - Drug Profile 92
  • AGN-241689 - Drug Profile 93
  • ALD-1910 - Drug Profile 94
  • ALD-403 - Drug Profile 95
  • AMG-301 - Drug Profile 99
  • AST-003 - Drug Profile 100
  • Atogepant - Drug Profile 101
  • BF-1 - Drug Profile 102
  • C-012 - Drug Profile 103
  • cloxyquin - Drug Profile 104
  • Deina - Drug Profile 105
  • dexisometheptene - Drug Profile 106
  • DFN-02 - Drug Profile 107
  • DFN-10 - Drug Profile 108
  • DFN-14 - Drug Profile 109
  • DFN-15 - Drug Profile 110
  • DFN-19 - Drug Profile 111
  • DFN-42 - Drug Profile 112
  • dihydroergotamine mesylate - Drug Profile 113
  • dihydroergotamine mesylate - Drug Profile 118
  • DIS-COM-TROP - Drug Profile 119
  • DORA-12 - Drug Profile 120
  • Drug 1 for Migraine and Cancer Pain - Drug Profile 121
  • Drug 2 for Migraine and Cancer Pain - Drug Profile 122
  • Drug 3 for Migraine and Cancer Pain - Drug Profile 123
  • Drug for Migraine - Drug Profile 124
  • Drug for Migraine and Cancer Pain - Drug Profile 125
  • erenumab - Drug Profile 126
  • Estetrol - Drug Profile 129
  • flunarizine hydrochloride - Drug Profile 132
  • galcanezumab - Drug Profile 133
  • histamine dihydrochloride - Drug Profile 135
  • ketoprofen - Drug Profile 136
  • KL-00204 - Drug Profile 138
  • lasmiditan succinate - Drug Profile 139
  • MK-8031 - Drug Profile 144
  • MTR-106 - Drug Profile 145
  • Nociceptin - Drug Profile 146
  • NOXL-41 - Drug Profile 147
  • NXN-188 - Drug Profile 148
  • NXN-462 - Drug Profile 150
  • oxytocin - Drug Profile 151
  • picotamide - Drug Profile 153
  • propofol hemisuccinate - Drug Profile 154
  • Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 155
  • rizatriptan benzoate - Drug Profile 156
  • rizatriptan benzoate - Drug Profile 159
  • rizatriptan benzoate - Drug Profile 160
  • RT-001 - Drug Profile 161
  • Small Molecule to Antagonize CALCRL for Migraine - Drug Profile 163
  • Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile 164
  • Small Molecule to Antagonize Kappa Opioid Receptor for Migraine - Drug Profile 165
  • Small Molecule to Inhibit CGRP for Migraine - Drug Profile 166
  • Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 167
  • Small Molecule to Inhibit nNOS and NET for Migraine and Neuropathic Pain - Drug Profile 168
  • Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 169
  • Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine - Drug Profile 170
  • Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 171
  • Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 172
  • SST-8055 - Drug Profile 173
  • sumatriptan succinate - Drug Profile 174
  • sumatriptan succinate - Drug Profile 176
  • sumatriptan succinate - Drug Profile 177
  • sumatriptan succinate - Drug Profile 178
  • TEV-48125 - Drug Profile 179
  • Tribarcina - Drug Profile 183
  • TRV-250 - Drug Profile 184
  • ubrogepant - Drug Profile 185
  • zolmitriptan - Drug Profile 187
  • zolmitriptan - Drug Profile 188
  • zolmitriptan - Drug Profile 190
  • zolmitriptan - Drug Profile 191
  • Migraine - Dormant Projects 192
  • Migraine - Discontinued Products 199
  • Migraine - Product Development Milestones 200
  • Featured News & Press Releases 200
  • Appendix 215
  • Methodology 215
  • Coverage 215
  • Secondary Research 215
  • Primary Research 215
  • Expert Panel Validation 215
  • Contact Us 215
  • Disclaimer 216

List of Tables

  • Number of Products under Development for Migraine, H2 2016 16
  • Number of Products under Development for Migraine - Comparative Analysis, H2 2016 17
  • Number of Products under Development by Companies, H2 2016 19
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 20
  • Number of Products under Development by Companies, H2 2016 (Contd..2) 21
  • Number of Products under Investigation by Universities/Institutes, H2 2016 22
  • Comparative Analysis by Late Stage Development, H2 2016 23
  • Comparative Analysis by Clinical Stage Development, H2 2016 24
  • Comparative Analysis by Early Stage Development, H2 2016 25
  • Comparative Analysis by Unknown Stage Development, H2 2016 26
  • Products under Development by Companies, H2 2016 27
  • Products under Development by Companies, H2 2016 (Contd..1) 28
  • Products under Development by Companies, H2 2016 (Contd..2) 29
  • Products under Development by Companies, H2 2016 (Contd..3) 30
  • Products under Investigation by Universities/Institutes, H2 2016 31
  • Migraine - Pipeline by Achelios Therapeutics Inc, H2 2016 32
  • Migraine - Pipeline by Acorda Therapeutics Inc, H2 2016 33
  • Migraine - Pipeline by Afferent Pharmaceuticals Inc, H2 2016 34
  • Migraine - Pipeline by Alder Biopharmaceuticals Inc, H2 2016 35
  • Migraine - Pipeline by Allergan Plc, H2 2016 36
  • Migraine - Pipeline by Amgen Inc, H2 2016 37
  • Migraine - Pipeline by Aralez Pharmaceuticals Inc, H2 2016 38
  • Migraine - Pipeline by Astellas Pharma Inc, H2 2016 39
  • Migraine - Pipeline by Biofrontera AG, H2 2016 40
  • Migraine - Pipeline by BioHealthonomics Inc, H2 2016 41
  • Migraine - Pipeline by Bristol-Myers Squibb Company, H2 2016 42
  • Migraine - Pipeline by Charleston Laboratories Inc, H2 2016 43
  • Migraine - Pipeline by CoLucid Pharmaceuticals Inc, H2 2016 44
  • Migraine - Pipeline by Corium International Inc, H2 2016 45
  • Migraine - Pipeline by Eli Lilly and Company, H2 2016 46
  • Migraine - Pipeline by Impel NeuroPharma Inc, H2 2016 47
  • Migraine - Pipeline by InStar Technologies AS, H2 2016 48
  • Migraine - Pipeline by Klaria Pharma Holding AB, H2 2016 49
  • Migraine - Pipeline by Medestea Research & Production SpA, H2 2016 50
  • Migraine - Pipeline by Merck & Co Inc, H2 2016 51
  • Migraine - Pipeline by Mithra Pharmaceuticals SA, H2 2016 52
  • Migraine - Pipeline by Monosol Rx LLC, H2 2016 53
  • Migraine - Pipeline by NAL Pharmaceuticals Ltd, H2 2016 54
  • Migraine - Pipeline by Noxxon Pharma AG, H2 2016 55
  • Migraine - Pipeline by Otsuka Holdings Co Ltd, H2 2016 56
  • Migraine - Pipeline by Promius Pharma LLC, H2 2016 57
  • Migraine - Pipeline by RedHill Biopharma Ltd, H2 2016 58
  • Migraine - Pipeline by Revance Therapeutics Inc, H2 2016 59
  • Migraine - Pipeline by Shin Nippon Biomedical Laboratories Ltd, H2 2016 60
  • Migraine - Pipeline by Strategic Science & Technologies LLC, H2 2016 61
  • Migraine - Pipeline by Suda Ltd, H2 2016 62
  • Migraine - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 63
  • Migraine - Pipeline by TheraJect Inc, H2 2016 64
  • Migraine - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2016 65
  • Migraine - Pipeline by Trevena Inc, H2 2016 66
  • Migraine - Pipeline by Trigemina Inc, H2 2016 67
  • Migraine - Pipeline by TrioxBio Inc, H2 2016 68
  • Migraine - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 69
  • Migraine - Pipeline by Xenon Pharmaceuticals Inc, H2 2016 70
  • Migraine - Pipeline by Zosano Pharma Corp, H2 2016 71
  • Assessment by Monotherapy Products, H2 2016 72
  • Assessment by Combination Products, H2 2016 73
  • Number of Products by Stage and Target, H2 2016 75
  • Number of Products by Stage and Mechanism of Action, H2 2016 80
  • Number of Products by Stage and Route of Administration, H2 2016 85
  • Number of Products by Stage and Molecule Type, H2 2016 87
  • Migraine - Dormant Projects, H2 2016 197
  • Migraine - Dormant Projects (Contd..1), H2 2016 198
  • Migraine - Dormant Projects (Contd..2), H2 2016 199
  • Migraine - Dormant Projects (Contd..3), H2 2016 200
  • Migraine - Dormant Projects (Contd..4), H2 2016 201
  • Migraine - Dormant Projects (Contd..5), H2 2016 202
  • Migraine - Dormant Projects (Contd..6), H2 2016 203
  • Migraine - Discontinued Products, H2 2016 204

List of Figures

  • Number of Products under Development for Migraine, H2 2016 16
  • Number of Products under Development for Migraine - Comparative Analysis, H2 2016 17
  • Number of Products under Development by Companies, H2 2016 18
  • Number of Products under Investigation by Universities/Institutes, H2 2016 22
  • Comparative Analysis by Late Stage Development, H2 2016 23
  • Comparative Analysis by Clinical Stage Development, H2 2016 24
  • Comparative Analysis by Early Stage Products, H2 2016 25
  • Assessment by Monotherapy Products, H2 2016 72
  • Assessment by Combination Products, H2 2016 73
  • Number of Products by Top 10 Targets, H2 2016 74
  • Number of Products by Stage and Top 10 Targets, H2 2016 74
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 79
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 79
  • Number of Products by Routes of Administration, H2 2016 84
  • Number of Products by Stage and Routes of Administration, H2 2016 84
  • Number of Products by Molecule Types, H2 2016 86
  • Number of Products by Stage and Molecule Types, H2 2016 86
Back to Top